ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Sunday, November 7, 2021

8:30AM-10:30AM: Abstract Number: 0834

Comparative Effectiveness of TNF Inhibitor vs IL-6 Receptor Inhibitor as Monotherapy or Combination Therapy with Methotrexate in Patients with Rheumatoid Arthritis: Analysis from CorEvitas’ RA Registry

RA – Treatments Poster I: Comparative Effectiveness, Biosimilars, Withdrawal, & the Real World (0813–0845)

8:30AM-10:30AM: Abstract Number: 0839

Comparative Treatment Effectiveness in Rheumatoid Arthritis with and Without Concomitant Sjögren’s Syndrome – Results from the Swiss Clinical Quality Management Cohort

RA – Treatments Poster I: Comparative Effectiveness, Biosimilars, Withdrawal, & the Real World (0813–0845)

8:30AM-10:30AM: Abstract Number: 0899

Comparison of Sacroiliac CT Findings in Patients with and Without Ankylosing Spondylitis Aged 50 Years or Older: Preliminary Results of the CASIAGE Study

Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster II: Imaging in Spondyloarthritis (0897–0907)

8:30AM-10:30AM: Abstract Number: 0869

Comparison of Two Frailty Definitions in Women with Systemic Lupus Erythematosus

SLE – Diagnosis, Manifestations, & Outcomes Poster II: Manifestations (0855–0896)

8:30AM-10:30AM: Abstract Number: 0617

Concerns and Beliefs About COVID-19 Vaccination Among Racial and Ethnic Minority Patients with Rheumatic Disease

Healthcare Disparities in Rheumatology Poster (0594–0622)

8:30AM-10:30AM: Abstract Number: 0671

Concomitant Immunomodulation and Pegloticase Therapy: Experiences with a Variety of Immunomodulatory Agents in Two Community Rheumatology Practices

Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)

8:30AM-10:30AM: Abstract Number: 0854

Confirmatory Factor Analysis of the Fatigue Assessment Instrument and Fatigue Severity Scale in Systemic Sclerosis

Research Methodology Poster (0846–0854)

8:30AM-10:30AM: Abstract Number: 0832

Consistency in Time to Response with Upadacitinib as Monotherapy or Combination Therapy and Across Patient Populations with Rheumatoid Arthritis

RA – Treatments Poster I: Comparative Effectiveness, Biosimilars, Withdrawal, & the Real World (0813–0845)

8:30AM-10:30AM: Abstract Number: 0568

Construction of the Veterans Affairs National Rheumatoid Arthritis Database (VANRAD)

Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)

8:30AM-10:30AM: Abstract Number: 0739

Contextual Factors Should Complete the Assessment of Functioning in Patients with Axial Spondyloarthritis (axSpA)

Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)

8:30AM-10:30AM: Abstract Number: 0636

Contraceptive and Pre-conception Counseling in an Academic Rheumatology Practice: A Needs Assessment to Identify Gaps in Care

Measures & Measurement of Healthcare Quality Poster (0623–0659)

8:30AM-10:30AM: Abstract Number: 0793

Contributing Factors of Good Outcome in Difficult-to-treat Rheumatoid Arthritis: A Multicenter RA Ultrasound Prospective Observational Cohort Study in Japan

RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)

8:30AM-10:30AM: Abstract Number: 0529

COPA Syndrome-associated Mutations in Lung Transplant Recipients for Interstitial Lung Disease

Genetics, Genomics & Proteomics Poster (0517–0533)

8:30AM-10:30AM: Abstract Number: 0806

Coping with Recent-onset Rheumatoid Arthritis (RA): Validation of the Coping with Health Injuries and Problems (CHIP) Questionnaire in a Longitudinal Cohort

RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)

8:30AM-10:30AM: Abstract Number: 0635

Correlation Between Provider Documentation and Patient Experience with Contraceptive Counseling in an Academic Rheumatology Practice

Measures & Measurement of Healthcare Quality Poster (0623–0659)

«Previous Page
1
…
5
6
7
8
9
…
34
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].